ESSA Pharma (NASDAQ:EPIX) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Posted by Tech Dows on Dec 18th, 2024

ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) released its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05, Zacks reports.

ESSA Pharma Stock Performance

Shares of NASDAQ EPIX opened at $1.64 on Wednesday. The business has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $4.63. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The stock has a market cap of $72.77 million, a price-to-earnings ratio of -2.65 and a beta of 1.62.

Analyst Upgrades and Downgrades

EPIX has been the topic of a number of research analyst reports. Oppenheimer downgraded shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, November 4th. Jefferies Financial Group cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, Piper Sandler downgraded shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $2.00 in a research note on Monday, November 4th.

View Our Latest Stock Report on EPIX

Insider Activity at ESSA Pharma

In related news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $1.53, for a total value of $12,055,761.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 14.70% of the company’s stock.

About ESSA Pharma

(Get Free Report)

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.